keyword
MENU ▼
Read by QxMD icon Read
search

Ozurdex

keyword
https://www.readbyqxmd.com/read/27915343/intravitreal-dexamethasone-implant-for-the-treatment-of-postoperative-macular-edema
#1
André Klamann, Katharina Böttcher, Philipp Ackermann, Gerd Geerling, Marc Schargus, Rainer Guthoff
INTRODUCTION: Macular edema after cataract surgery (Irvine-Gass syndrome) or pars plana vitrectomy is a postoperative complication which can lead to permanent visual loss. Increased inflammatory substances, such as prostaglandins and cytokines, are discussed to be causative. Currently, there are no evidence-based guidelines for the treatment of postoperative macular edema. Intravitreal dexamethasone (DEX) could be effective by its anti-inflammatory effect. We examined the functional and morphological results of treatment with 0...
December 3, 2016: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/27893624/prospective-evaluation-of-a-sustained-release-dexamethasone-intravitreal-implant-for-cystoid-macular-edema-in-quiescent-uveitis
#2
Rahul N Khurana, Alok S Bansal, Louis K Chang, James D Palmer, Chengqing Wu, Mark R Wieland
PURPOSE: To investigate dexamethasone intravitreal implant (DEX implant; OZURDEX, Allergan, Inc) in the treatment of uveitic cystoid macular edema that had persisted in the absence of intraocular inflammation. METHODS: In this prospective interventional case series, 10 patients with uveitic cystoid macular edema and quiescent uveitis were treated with dexamethasone intravitreal implant at baseline and evaluated monthly for one year. Patients were retreated whenever cystoid macular edema recurred...
November 23, 2016: Retina
https://www.readbyqxmd.com/read/27882244/evaluation-of-peripapillary-nerve-fiber-layer-after-dexamethasone-implantation-ozurdex-in-branch-retinal-vein-occlusions
#3
Muhammed Nurullah Bulut, Yusuf Özertürk, Ümit Çallı, Güzide Akçay, Ulviye Kıvrak, Kezban Bulut
Purpose. To evaluate the peripapillary retinal nerve fiber layer (RNFL) thicknesses of patients treated with intravitreal Ozurdex implant due to branch retinal vein occlusion (BRVO) related macular edema (ME). Methods. Thirty-three eyes of 33 patients treated with Ozurdex implant due to ME associated with BRVO were included in the study. Ophthalmic examinations including determination of best corrected visual acuity (BCVA), measurement of intraocular pressure (IOP), and central macular thickness (CMT) and peripapillary RNFL assessment with optical coherence tomography (OCT) were performed before the injection of Ozurdex implant and during the 6-month follow-up period after the injection...
2016: Journal of Ophthalmology
https://www.readbyqxmd.com/read/27806001/ocular-hypertension-after-intravitreal-dexamethasone-ozurdex-sustained-release-implant
#4
Eric K Chin, David R P Almeida, Gabriel Velez, Kunyong Xu, Maria Peraire, Maria Corbella, Yasser M Elshatory, Young H Kwon, Karen M Gehrs, H Culver Boldt, Elliott H Sohn, Stephen R Russell, James C Folk, Vinit B Mahajan
PURPOSE: To evaluate ocular hypertension (OHT) after Ozurdex injection to determine the incidence of OHT, therapy for OHT, and any associative factors such as diagnosis, underlying glaucoma and therapy, or sequential Ozurdex injection(s). METHODS: Retrospective consecutive case series with patients receiving one or more intravitreal Ozurdex implantations at a tertiary care academic center. Ocular hypertension was defined as a single measurement of ≥30 mmHg or an increase of ≥10 mmHg from baseline...
November 1, 2016: Retina
https://www.readbyqxmd.com/read/27803859/an-eighteen-month-follow-up-study-on-the-effects-of-intravitreal-dexamethasone-implant-in-diabetic-macular-edema-refractory-to-anti-vegf-therapy
#5
Fernanda Pacella, Maria Rosaria Romano, Paolo Turchetti, Giovanna Tarquini, Anna Carnovale, Antonella Mollicone, Alessandra Mastromatteo, Elena Pacella
AIM: To evaluate the long-term efficacy and safety of dexamethasone implants in subjects affected by diabetic macular edema (DME) resistant to anti-vascular endothelial growth factor (VEGF) therapy. METHODS: Thirty-two DME patients were enrolled. A 700 microgram slow release Intravitreal Dexamethasone Implant (Ozurdex(®)) was placed in the vitreous cavity. All patients were followed for 18mo. Best-corrected visual acuity (BCVA) measured with Early Treatment Diabetic Retinopathy Study (ETDRS) and central macular thickness (CMT) exams were carried out at baseline (T0) and after 1 (T1), 3 (T3), 4 (T4), 6 (T6), 9 (T9), 12 (T12), 15 (T15), and 18mo (T18) post injection...
2016: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/27800199/-magic-bullet-eccentric-macular-hole-as-a-complication-from-dexamethasone-implant-insertion
#6
Logan Christensen, Riley Sanders, Jeffrey Olson
Introduction. Intravitreal drug injections and implants are generally safe but do carry some risk, from both the procedure itself and adverse effects of the medications. We report a case of an eccentric macular hole after dexamethasone implant (Ozurdex®) administration. Ex vitro force testing was performed to evaluate dexamethasone implant injection force. Methods. Five dexamethasone implant (Ozurdex) applicators were placed 16 mm from a force plate and the force of the injected dexamethasone pellet was recorded in Newtons...
2016: Case Reports in Ophthalmological Medicine
https://www.readbyqxmd.com/read/27778454/quantification-of-fluid-resorption-from-diabetic-macular-oedema-with-foveal-serous-detachment-after-dexamethasone-intravitreal-implant-ozurdex-%C3%A2-in-a-pregnant-diabetic
#7
Delila Hodzic-Hadzibegovic, Shakoor Ba-Ali, Marianne Valerius, Henrik Lund-Andersen
PURPOSE: To quantify the fluid resorption from the centre of the fovea in a pregnant woman with diabetic macular oedema by daily optical coherence tomography (OCT) measurements after the administration of intravitreal dexamethasone implant (Ozurdex(®) ). METHODS: A 36-year-old pregnant woman with type 1 diabetes for 33 years presented with diabetic macular oedema with foveal serous detachment and symptomatic vision loss at 16 gestational weeks. Best-corrected visual acuity (BCVA) in Snellen notation and central retinal volume assessed by optical coherence tomography (OCT, Topcon Corporation) were measured almost on a daily basis the first five weeks after implantation and then 2-3 times per month until childbirth...
October 24, 2016: Acta Ophthalmologica
https://www.readbyqxmd.com/read/27768792/vision-related-quality-of-life-outcomes-in-the-bevordex-study-a-clinical-trial-comparing-ozurdex-sustained-release-dexamethasone-intravitreal-implant-and-bevacizumab-treatment-for-diabetic-macular-edema
#8
Christine Aroney, Samantha Fraser-Bell, Ecosse L Lamoureux, Mark C Gillies, Lyndell L Lim, Eva K Fenwick
Purpose: To determine the patient-centered effectiveness of treatment with the slow-release dexamethasone intravitreal implant (DEX implant) and intravitreal bevacizumab using the Impact of Vision Impairment Questionnaire (IVI), a vision-related quality of life (VRQoL) measure, in patients with visual impairment secondary to center-involving diabetic macular edema (DME). Methods: Patients with DME were enrolled in a phase 2, prospective, multicenter, randomized, single-masked clinical trial and received either DEX implant 4 monthly or bevacizumab monthly, both pro re nata...
October 1, 2016: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/27768641/safety-of-intravitreal-dexamethasone-implant-ozurdex-the-safodex-study-incidence-and-risk-factors-of-ocular-hypertension
#9
Ariane Malclès, Corinne Dot, Nicolas Voirin, Anne-Laure Vié, Émilie Agard, David Bellocq, Philippe Denis, Laurent Kodjikian
PURPOSE: To analyze the incidence, risk factors, and time course of intraocular pressure elevation after intravitreal dexamethasone implant (Ozurdex). METHODS: The medical charts of 421 consecutive eyes (361 patients) receiving one or more Ozurdex implant between October 2010 and February 2015 were reviewed retrospectively. Ocular hypertension was defined as intraocular pressure of at least 25 mmHg or an increase of at least 10 mmHg from baseline. The main indications for treatment were retinal vein occlusion (34%), diabetic macular edema (30%), postsurgical macular edema (17%), uveitis (14%), and other etiologies (5%)...
October 20, 2016: Retina
https://www.readbyqxmd.com/read/27733187/management-of-anterior-chamber-dislocation-of-a-dexamethasone-intravitreal-implant-a-case-report
#10
Fernanda Pacella, Enzo Agostinelli, Sandra Cinzia Carlesimo, Marcella Nebbioso, Roberto Secondi, Michele Forastiere, Elena Pacella
BACKGROUND: Ozurdex is a 700 mcg dexamethasone intravitreal implant, approved for the management of macular edema secondary to retinal vein occlusion, and other related pathoglogiesAnterior chamber dislocation of Ozurdex represents an uncommon complication of the intravitreal injection, which can be managed by repositioning the implant into the vitreous cavity. We describe the case of a successful repositioning of an Ozurdex implant by mobilization and subsequent balanced saline solution injection in the anterior chamber...
October 13, 2016: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/27626149/short-term-effects-of-intravitreal-dexamethasone-implant-ozurdex%C3%A2-on-choroidal-thickness-in-patients-with-naive-branch-retinal-vein-occlusion
#11
Hasan Basri Arifoglu, Necati Duru, Orhan Altunel, Burhan Baskan, Bedirhan Alabay, Mustafa Atas
PURPOSE: The objective of this study was to evaluate subfoveal choroidal thickness (SFCT) using enhanced depth imaging optical coherence tomography (EDI-OCT) in patients with naïve branch retinal vein occlusion (BRVO) before and after intravitreal dexamethasone implant (Ozurdex®) injection. METHODS: Thirty-nine patients with unilateral BRVO and 35 healthy subjects were included in this prospective study. Choroidal thickness was evaluated by EDI-OCT at baseline and 1 month after dexamethasone implant...
July 2016: Arquivos Brasileiros de Oftalmologia
https://www.readbyqxmd.com/read/27612922/comparison-of-dexamethasone-intravitreal-implant-with-conventional-triamcinolone-in-patients-with-postoperative-cystoid-macular-edema
#12
Georgios Mylonas, Michael Georgopoulos, Panagiotis Malamos, Ilias Georgalas, Chryssanthi Koutsandrea, Dimitrios Brouzas, Stefan Sacu, Christos Perisanidis, Ursula Schmidt-Erfurth
AIMS: To evaluate the efficacy of the treatment with intravitreal triamcinolone acetonide or dexamethasone intravitreal implant in patients with postoperative cystoid macular edema (PCME). MATERIALS AND METHODS: Thirty eyes of 29 patients with PCME were randomized into two groups: one group initially received an injection of 4 mg triamcinolone; retreatment after 3 months was dependent on functional and anatomic outcome in a PRN regimen. The second group received a single injection of the dexamethasone intravitreal implant (Ozurdex)...
September 9, 2016: Current Eye Research
https://www.readbyqxmd.com/read/27599562/the-effect-of-age-on-dexamethasone-intravitreal-implant-ozurdex%C3%A2-response-in-macular-edema-secondary-to-branch-retinal-vein-occlusion
#13
Orhan Altunel, Altan Göktaş, Necati Duru, Ayşe Özköse, Hasan Basri Arifoğlu, Mustafa Ataş
PURPOSE: To investigate the effect of age on dexamethasone intravitreal implant (Ozurdex®) response in macular edema secondary to branch retinal vein occlusion (BRVO). METHODS: Seventy-three eyes of 73 patients with macular edema secondary to BRVO were recruited in the study. The patients in the study were divided into the following four groups according to their ages: group 1 (<60 years), group 2 (60-69 years), group 3 (70-79 years), and group 4 (≥80 years)...
September 6, 2016: Seminars in Ophthalmology
https://www.readbyqxmd.com/read/27599154/intravitreal-ozurdex-%C3%A2-implantation-after-boston-type-i-keratoprosthesis
#14
Sushmita G Shah, Vatsal S Parikh, Roberto Pineda
No abstract text is available yet for this article.
September 6, 2016: Ocular Immunology and Inflammation
https://www.readbyqxmd.com/read/27560847/atypical-presentation-of-chorioretinal-folds-related-maculopathy
#15
Federico Corvi, Vittorio Capuano, Lucia Benatti, Francesco Bandello, Eric Souied, Giuseppe Querques
PURPOSE: Chorioretinal folds are undulations that anatomically include the inner choroid, Bruch's membrane, and the retinal pigment epithelium, and secondarily affect the overlying neurosensory retina. We analyzed clinical data and management of six patients diagnosed with chorioretinal folds-related maculopathy with atypical presentations. CASE REPORT: The mean age of the six patients (five women) was 77 years. Best-corrected visual acuity (BCVA) ranged between 20/200 and 20/80...
October 2016: Optometry and Vision Science: Official Publication of the American Academy of Optometry
https://www.readbyqxmd.com/read/27540825/intravitreal-dexamethasone-implant-ozurdex-to-control-recurrent-severe-idiopathic-uveitis-leads-to-improvement-in-steroid-induced-diabetes-mellitus
#16
Ashraf A Khan, Georgios Kontos, Sheila P Paterson-Brown, Baljean Dhillon
Steroid-induced diabetes mellitus (SIDM) poses a unique challenge for the physician and ophthalmologist when faced with chronic recurrent uveitis controlled only with systemic steroids. We report a unique case where SIDM improved significantly following administration of intravitreal dexamethasone. A 53-year-old female had a history of recurrent idiopathic anterior uveitis that required oral steroids for control despite orbital floor steroids and systemic immunosuppression. After 9 years of oral steroid treatment she was diagnosed with SIDM necessitating insulin therapy...
August 19, 2016: Ocular Immunology and Inflammation
https://www.readbyqxmd.com/read/27521672/ozurdex-in-age-related-macular-degeneration-as-adjunct-to-ranibizumab-the-oara-study
#17
Varun Chaudhary, Joshua Barbosa, Wai-Ching Lam, Michael Mak, Emmanouil Mavrikakis, S Mohammad Mohaghegh P
OBJECTIVE: To evaluate the utility of dexamethasone intravitreal implant (DXI; Ozurdex; Allergan, Irvine, Calif.) in combination with ranibizumab (Lucentis; Novartis Pharma AG, Basel, Switzerland) versus ranibizumab monotherapy on visual acuity (VA) and anatomical outcomes in a neovascular age-related macular degeneration (nAMD) cohort. DESIGN: Multicentred, single-blinded, pilot randomized control trial. PARTICIPANTS: Ten patients 50 years or older with subfoveal choroidal neovascularization secondary to AMD were randomized to receive DXI in combination with ranibizumab (group 1) or ranibizumab alone (group 2) after a 3-month ranibizumab loading period...
August 2016: Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie
https://www.readbyqxmd.com/read/27508424/quiescent-herpes-simplex-keratitis-reactivation-after-intravitreal-injection-of-dexamethasone-implant
#18
Denis Jusufbegovic, Shlomit Schaal
PURPOSE: To report reactivation of herpes simplex virus keratitis after the injection of dexamethasone implant (Ozurdex) and to raise the awareness of this potentially vision threatening side effect. METHODS: A 90-year-old man presented with ocular pain and tearing in the left eye 3 weeks after receiving a dexamethasone implant (Ozurdex) for the treatment of macular edema associated with branch retinal vein occlusion. The patient had a history of herpes simplex virus keratitis that was quiescent for more than 30 years...
August 9, 2016: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/27479780/response-of-postoperative-and-chronic-uveitic-cystoid-macular-edema-to-a-dexamethasone-based-intravitreal-implant-ozurdex
#19
Justus G Garweg, Edoardo Baglivo, Florentina J Freiberg, Maximilian Pfau, Isabel B Pfister, Stephan Michels, Souska Zandi
PURPOSE: To survey the clinical responses to treatment of chronic postoperative and uveitic cystoid macular edema (CME) with a dexamethasone-based intravitreal implant (Ozurdex(®)). METHODS: This retrospective, interventional case series reports on patients with chronic CME after uncomplicated vitrectomy for epiretinal gliosis or phacoemulsification (group 1: 12 eyes) or secondary to noninfectious endogenous uveitis (group 2: 36 eyes). Central retinal thickness (CRT), best-corrected visual acuity (BCVA, logMAR), and intraocular pressure (IOP) throughout follow-up were gleaned from the medical records...
September 2016: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/27471826/real-life-study-in-diabetic-macular-edema-treated-with-dexamethasone-implant-the-reldex-study
#20
Ariane Malclès, Corinne Dot, Nicolas Voirin, Émilie Agard, Anne-Laure Vié, David Bellocq, Philippe Denis, Laurent Kodjikian
PURPOSE: To evaluate the efficacy and safety of intravitreal implant of dexamethasone (Ozurdex) in diabetic macular edema in real-life practice. METHODS: In this bicentric retrospective study, the authors reviewed 128 eyes of 89 patients. Main outcome measures included changes in best-corrected visual acuity, central macular thickness, time to retreatment, and incidence of adverse effects. Linear mixed-effects models were used to study changes in best-corrected visual acuity and central macular thickness over the 3-year follow-up...
July 28, 2016: Retina
keyword
keyword
33543
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"